Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Xiaoliu granules II formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by the First Affiliated Hospital of Henan University of TCM. It is primarily investigated as an adjuvant treatment for patients with stage II hepatocellular carcinoma (HCC) related to chronic hepatitis B virus (HBV) infection who have undergone minimally invasive surgery. The formula is designed to improve the 1-year clinical benefit rate and delay disease progression by potentially enhancing the host's immune response and inhibiting tumor recurrence. As a TCM formula, it consists of multiple botanical ingredients intended to 'strengthen the body's resistance' (Fuzheng) and 'eliminate tumors' (Xiaoliu).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fuzheng xiaoliu granules II formula.